Show simple item record

dc.contributor.authorMcKee, Michael D
dc.contributor.authorLitchfield, Robert
dc.contributor.authorHall, Jeremy A
dc.contributor.authorWester, Tawana
dc.contributor.authorJones, John
dc.contributor.authorHarrison, Andrew J
dc.date.accessioned2019-08-05T20:48:48Z
dc.date.available2019-08-05T20:48:48Z
dc.date.issued2019-06
dc.identifier.citationMcKee, M. D., Litchfield, R., Hall, J. A., Wester, T., Jones, J., & Harrison, A. J. (2019). NASHA hyaluronic acid for the treatment of shoulder osteoarthritis: a prospective, single-arm clinical trial. Medical Devices (Auckland, NZ), 12, 227.en_US
dc.identifier.issn1179-1470
dc.identifier.doi10.2147/mder.s189522
dc.identifier.urihttp://hdl.handle.net/10150/633665
dc.description.abstractBackground: Osteoarthritis of the shoulder or glenohumeral joint is a painful condition that can be debilitating. Intra-articular injection with hyaluronic acid should be considered for patients not responding adequately to physical therapy or anti-inflammatory medication. Methods: This was a single-arm, open-label, prospective study of a single intra-articular injection of NASHA (non-animal hyaluronic acid) in patients with symptomatic glenohumeral osteoarthritis. Patients were followed up for 26 weeks post-treatment, during which time rescue medication with acetaminophen was permissible. The study objective was to demonstrate that a single injection of NASHA is well tolerated with an over-6-month 25% reduction in shoulder pain on movement, assessed using a 100-mm visual analog scale. Results: Forty-one patients were enrolled, all of whom received study treatment. The mean decrease in shoulder pain on movement score over the 6-month study period was -20.1 mm (95% CI: -25.2, -15.0 mm), corresponding to a mean reduction of 29.5% (22.0, 37.0%). Statistically significant improvements were also observed in shoulder pain at night and patient global assessment. There was no clear change over time in the percentage of patients using rescue medication and mean weekly doses were below 3500 mg. Seventeen patients (41.5%) experienced adverse events, all of which were mild or moderate. Two adverse events (both shoulder pain) were deemed related to study treatment. Conclusion: This study provides preliminary evidence that a single injection of NASHA may be efficacious over 6 months and well tolerated in patients with symptomatic glenohumeral osteoarthritis. Larger studies are needed for confirmation.en_US
dc.description.sponsorshipBioventus LLC, Durham, NC, USAen_US
dc.language.isoenen_US
dc.publisherDove Medical Press Ltd.en_US
dc.rightsCopyright © 2019 McKee et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectDurolane (R)en_US
dc.subjectglenohumeral jointen_US
dc.subjectnon-animal hyaluronic aciden_US
dc.subjectosteoarthritisen_US
dc.subjectshoulderen_US
dc.subjectviscosupplementationen_US
dc.titleNASHA hyaluronic acid for the treatment of shoulder osteoarthritis: a prospective, single-arm clinical trialen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Meden_US
dc.identifier.journalMEDICAL DEVICES-EVIDENCE AND RESEARCHen_US
dc.description.noteOpen access journalen_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.volumeVolume 12
dc.source.beginpage227-234
refterms.dateFOA2019-08-05T20:48:49Z


Files in this item

Thumbnail
Name:
mder-189522-nasha-hyaluronic-a ...
Size:
336.1Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

Copyright © 2019 McKee et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).
Except where otherwise noted, this item's license is described as Copyright © 2019 McKee et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).